Hengrui Launches Apatinib With Echoes Of Icotinib Approach
This article was originally published in PharmAsia News
Jiangsu Hengrui is going all out for its apatinib launch, combining a follow-on study and patient assistance with post-marketing research and local reimbursement talks. Will the comprehensive strategy work for the gastric cancer drug like it has for Betta in the lung cancer market?
You may also be interested in...
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.